Lipid targets can be difficult to attain in familial B5A1 ratios. Eleven patients (20.4%) had sideeffects: two discontinued atorvastatin due to sidehypercholesterolaemia. To compare atorvastatin with simvastatin-fenofibrate and simvastatineffects; two patients had rashes; six had myalgia and two had diarrhoea. Gastrointestinal side-effects cholestyramine therapy, we studied 54 patients with familial hypercholesterolaemia over periods of 2-6 were described in 16 (30.1%) patients on simvastatin-cholestyramine therapy and four cases of myalgia months on each therapeutic regimen. The atorvastatin regimen reduced total cholesterol by 41.2±
Introduction
Many patients with familial hypercholesterolaemia effects have not been compared with standard drug treatment regimens in patients with familial hyperchoprove difficult to control on single-agent therapy with lesterolaemia.5 In this paper, we describe our experia hydroxymethyl glutaryl (HMG)-CoA reductase inhibence with the use of high-dose atorvastatin compared itor.1-3 Most require additional therapy with a bile-acid with simvastatin-fenofibrate and simvastatinsequestrant, but many patients complain of side-effects cholestyramine combination therapy in patients with with these agents and in addition they interfere with severe familial hypercholesterolaemia. the absorption of other drugs. We have shown that a fenofibrate-simvastatin regime is superior to the established cholestyramine-simvastatin therapy, in spite of Methods anecdotal early reports of myopathy with the gemfibrozil-lovastatin and gemfibrozil-simvastatin combina-
The lipid clinics at Guy's and St. Thomas' hospitals tions.4 Atorvastatin, a novel HMGCoA reductase contain 370 patients with probable familial hyperchinhibitor, has been shown to achieve superior LDL olesterolaemia, of whom 68 have particular difficulty in attaining a LDL-cholesterol target of 3.5 mmol/l. reduction compared to other HMGCoA-Is, but its
In this study, we review the data on 54 patients aged Atorvastatin had little effect on apolipoprotein A1 concentrations compared to the other regimens, but 18-70 years with severe familial hypercholesterolaemia whose total cholesterol on maximal tolerated did significantly reduce apolipoprotein A2 in contrast to both other regimens (p=0.006, 0.005). therapy was >7 mmol/l. These patients were studied after 3 months therapy with 80 mg atorvastatin nocte Atorvastatin achieved a significantly larger reduction in apolipoprotein B concentration than the other having previously been on either combination therapy with simvastatin 40 mg nocte and fenofibrate regimens, but did not alter lipoprotein (a) concentrations. Atorvastatin achieved an LDL5HDL ratio of 200 mg mane or simvastatin 40 mg-cholestyramine 32 g/day therapy. All results were compared with 3.5 in 65% of patients, although it was not significantly better than the fenofibrate-simvastatin regimen values after 4 weeks off drug treatment prior to changing to the new combination.
(59%). Its disproportionate effects on apolipoprotein B resulted in slight improvements in the apolipoFasting blood samples were taken at each clinic visit, and stored at −20°C until analysed. Total protein B5A1 and apolipoprotein B5A1-A2 ratios of the balance of forward and reverse cholesterol transcholesterol, triglycerides and high-density lipoprotein (HDL) cholesterol were measured by standard port5apolipoprotein B5apolipoprotein A1 ratio compared with simvastatin-cholestyramine regimen but enzymic techniques and following manganesedextran precipitation for HDL-cholesterol. Lownot the simvastatin-fenofibrate regimen.
The commonest adverse events seen with atorvasdensity lipoprotein (LDL) cholesterol was calculated by the Freidewald equation. Apolipoprotein A1, A2, tatin were rash and myalgia (six patients), and gastrointestinal disturbance (diarrhoea) in three B 100 and lipoprotein (a) concentrations were determined by turbidimetry on a Cobas Fara II analyser.6 patients; two patients discontinued medication due to disabling myagia or severe diarrhoea. These all Samples for lipoprotein (a) analysis were pre-spun and lipase-treated to reduce triglyceride interferresolved 4 weeks after cessation of drug therapy.
With the combination therapies, severe gastrointestience.7 Possible side-effects of the medications were monitored by questioning patients and biochemically nal disturbance (nausea, flatus, abdominal pain, diarrhoea or constipation) was seen with the simvasby measurement of creatine kinase, aspartate transaminase and gamma-glutamyl transferase activities tatin-cholestyramine regimen (16 patients) (30.1%), with milder symptoms in the rest, whilst myalgia in plasma by conventional automated methods.
was reported in 4 (11.2%) patients with simvastatinfenofibrate therapy. Atorvastatin caused significant
Statistical analysis
transaminase (ALT>150 IU/l) rise in 3 patients. Distributions of all variables were analysed and using Overall transaminases and creatine kinase were geometric means for non-normally distributed variraised compared to baseline values (p=0.001) after able of triglyceride and lipoprotein (a). Groups of atorvastatin treatment, but this effect was not significdata were compared using paired Student's t tests ant when compared with the transaminase or creatine for the two drug regimens.
kinase changes seen on the other regimens. The study was performed with local ethical committee consent.
Discussion
Familial hypercholesterolaemia is associated with a Results marked increase in cardiovascular risk, and current drug-therapy regimens are often insufficient to The characteristics and results obtained from patients enrolled in the study are shown in Table 1 . All achieve the secondary or primary prevention lipid targets necessary to increase life expectancy in these patients tried simvastatin-cholestyramine therapy, although compliance with the cholestyramine was patients.1-3 Most studies have relied on the use of combination therapies of bile-acid sequestrant and variable, 36 tried the fenofibrate-simvastatin regimen and all tried atorvastatin. All regimens achieved hydroxy-methyl-glutaryl-CoA reductase inhibitors (HMGCoA-Is) to achieve additional LDL-cholesterol highly significant improvements in the lipid profile compared to pre-treatment values. The average reduction, but these agents are generally poorly tolerated, interfere with the absorption of other reductions achieved in these patients were 41.2±11.2% vs. 33.9±8.5% for total cholesterol medications, and have adverse effects on the overall lipid profile. We have shown that high-dose fibrateand 33.8±24.6% vs. 34.7±38.3% for triglycerides with atorvastatin as opposed to simvastatinHMGCoA-I combinations are as safe, more tolerable and biochemically superior to the use of HMGCoAfenofibrate therapy. HDL-cholesterol was increased by 2.3±37.0% on atorvastatin therapy and by I-bile acid sequestrant combinations.4 Atorvastatin has been shown to reduce total cho-25.4±55.1% on simvastatin-fenofibrate therapy. lesterol by 47.5%, triglycerides by 27.2%, LDL by triglycerides, and is superior to combination fibrateHMGCoA-I therapy and HMGCoA-I cholestyramine 61%, apolipoprotein B by 50.3% and lipoprotein (a) by 14.2% and to raise HDL by 3.4% and apolipotherapy in improving the lipid profile. However, at 80 mg doses, it causes more clinical and biochemical protein A1 by 0.8% in early trials in 11 patients at a 80 mg dose.5,8 At a dose of 10 mg, atorvastatin side-effects than fibrate-HMGCoA-I combination therapy, and can reduce HDL in some patients. reduces triglycerides by 25% compared to 46% with fenofibrate 100 mg tds.9 It thus offers the potential promise of a further simplification in therapy and additional benefits compared to previous HMGCoA-
